Roche Xeloda Combo With Taxotere Approved; Phase IV Dosing Study Planned
Executive Summary
Roche will submit the protocol for a Phase II study comparing three different dose regimens for Xeloda (capecitabine) by January 2002 as one of its postmarketing commitments following the Sept. 7 supplemental approval of the agent for use in combination with Aventis' Taxotere (docetaxel) to treat metastatic breast cancer.
You may also be interested in...
Xeloda-Warfarin Black Box Warning To Be Subject Of Roche Letter To Doctors
Roche is preparing a letter to physicians highlighting a black box warning about interactions between Xeloda (capecitabine) and warfarin following FDA's Sept. 7 approval of the labeling change.
Xeloda-Warfarin Black Box Warning To Be Subject Of Roche Letter To Doctors
Roche is preparing a letter to physicians highlighting a black box warning about interactions between Xeloda (capecitabine) and warfarin following FDA's Sept. 7 approval of the labeling change.
Roche Xeloda Colorectal Use Clears FDA; Promotions Must Cite Camptosar
Roche will study Xeloda in combination with Pharmacia's Camptosar in colorectal cancer patients following FDA approval of Xeloda April 30 for use in metastatic colorectal cancer patients.